CTNM Company Profile and Key Details

CTNM has shown mixed momentum, gaining 29.23% over the past week and 1.28% over the past quarter, though year-to-date performance is up 3.67%. Short-term trend indicators are bearishly aligned (SMA20 4.18%, SMA50 21.25%, SMA200 66.58%). The stock’s 14-day RSI is 63.4 (firm momentum), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.37% below its high and over 371.04% above its low. Average 10-day trading volume of 383.45 thousand shares is slightly above the 3-month average of 314.36 thousand, indicating heightened recent market interest.

Contineum Therapeutics, Inc. has 21.63 million shares outstanding. The public float is 14.97 million shares, elevated short interest at 3.19% of float. This equals 620.60 thousand shares. The short ratio is 2.51 days. Institutional investors hold 94.9% of the float. Insiders own 0.96%. Lorrain Daniel S. holds 135.20 thousand shares, Stengone Carmine N. has 17.22 thousand shares and Watkins Tim has 8.96 thousand shares. Over the past six months, insider transactions show net selling. They sold 89.21 thousand shares across 20 transactions.

Contineum Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.43. This means the shares are trading above this model’s fair value.

Contineum Therapeutics, Inc. (NASDAQ:CTNM) closed at $14.62 USD, losing -$0.57 (-3.75%) from the previous close of $15.19. The stock is currently mid-range between its 52-week high and low $3.72 and $16.91. With a market capitalization of about $546.59 million, Contineum Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.70). Key stats such as the average daily volume over the past year has been around 331.43 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Contineum Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carmine N. Stengone, the company employs approximately 51 people and listed since April 04, 2024. Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.

Wall Street analysts project EPS growth of 1.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $16.00. The high target offers 57.32% upside. The low target suggests 9.44% downside. The mean target is $19.71. This offers 34.82% upside. Contineum Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -29.09%. The prior quarter beat by -2.0%. Over the last six quarters, Apple has recorded several small beats. These include 27.27% in March 06, 2025.

Contineum Therapeutics, Inc. trades at a P/E ratio of -7.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.17 suggesting the stock is closer to book value. The P/FCF stands at -9.44, also below market averages.

Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are flat 3.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Contineum Therapeutics, Inc. trading at a premium to the broader market with a P/E of -7.47. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $22.08, suggesting 51.03% upside. Our AI forecast model points to short-term strength (15.8% over two weeks), a medium-term rise (313.2% over three months), and a longer-term gain (109.58% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Contineum Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.8%, with price expected at $16.93 by July 27, 2026, within a range of $16.01 to $17.88 3-Month Outlook: Projected rise of 313.2%, reaching $60.41 by October 08, 2026, with a range of $60.16 to $60.66. 1-Year Outlook: Projected gain of 109.58%, with price at $30.64 by July 13, 2027, within a range of $26.04 to $40.81.